Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
2026 · 2nd Quarter (Apr 1 - June 30)
CURRAX PHARMACEUTICALS LLC
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- 274d3c73-e908-4130-b50a-b964beb7ea1c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.